2018-12-12 22:51:00| Fool.com Headlines
The company updated investors on its financial performance, and on its progress developing RNAi therapies.
2018-12-12 22:12:00| Fool.com Headlines
A secondary offering on the way isn't what investors wanted to hear.
2018-12-11 23:06:00| Fool.com Headlines
Volatility strikes the biotech.
2018-12-11 21:29:00| Fool.com Headlines
Adamas Pharmaceuticals' valuation took yet another hit last month. Here's why.
2018-12-11 13:00:00| PR Newswire: Financial
ALISO VIEJO, Calif., Dec. 11, 2018 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. today announced that it will terminate the license agreement with Optinose for intranasal migraine medication ONZETRA Xsail (sumatriptan nasal powder). Optinose, of Yardley, Pa., is a global specialty...